Zhang Mingliang, Carter Chureen, Olson William H, Johnson Michael P, Brennem Susan K, Lee Seina, Farahi Kamyar
J Drugs Dermatol. 2017 Mar 1;16(3):220-226.
There is limited research exploring patient preferences regarding dosing frequency of biologic treatment of psoriasis.
Patients with moderate-to-severe plaque psoriasis identified in a healthcare claims database completed a survey regarding experience with psoriasis treatments and preferred dosing frequency. Survey questions regarding preferences were posed in two ways: (1) by likelihood of choosing once per week or 2 weeks, or 12 weeks; and (2) by choosing one option among once every 1-2 or 3-4 weeks or 1-2 or 2-3 months. Data were analyzed by prior biologic history (biologic-experienced vs biologic-naïve, and with one or two specific biologics).
Overall, 426 patients completed the survey: 163 biologic-naïve patients and 263 biologic-experienced patients (159 had some experience with etanercept, 105 with adalimumab, and 49 with ustekinumab). Among patients who indicated experience with one or two biologics, data were available for 219 (30 with three biologics and 14 did not specify which biologic experience). The majority of biologic-naïve (68.8%) and overall biologic-experienced (69.4%) patients indicated that they were very likely to choose the least frequent dosing option of once every 12 weeks (Table 1). In contrast, fewer biologic-naïve (9.1% and 16.7%) and biologic-experienced (22.5% and 25.3%) patients indicated that they were very likely to choose the 1-week and 2-week dosing interval options, respectively. In each cohort grouped by experience with specific biologics, among those with no experience with ustekinumab, the most chosen option was 1-2 weeks. The most frequently chosen option was every 2-3 months, among patients with any experience with ustekinumab, regardless of their experience with other biologics.
The least frequent dosing interval was preferred among biologic naïve patients and patients who had any experience with ustekinumab. Dosing interval may influence the shared decision-making process for psoriasis treatment with biologics.
J Drugs Dermatol. 2017;16(3):220-226.
.关于银屑病生物治疗给药频率的患者偏好研究有限。
在医疗保健理赔数据库中识别出的中重度斑块状银屑病患者完成了一项关于银屑病治疗经历和偏好给药频率的调查。关于偏好的调查问题以两种方式提出：（1）选择每周一次、每2周一次或每12周一次的可能性；（2）在每1 - 2周或3 - 4周、或1 - 2个月或2 - 3个月中选择一种。数据按既往生物制剂使用史（有生物制剂使用经验与无生物制剂使用经验，以及使用过一种或两种特定生物制剂）进行分析。
总体而言，426名患者完成了调查：163名无生物制剂使用经验的患者和263名有生物制剂使用经验的患者（159名有依那西普使用经验，105名有阿达木单抗使用经验，49名有乌司奴单抗使用经验）。在表示有一或两种生物制剂使用经验的患者中，有219名患者的数据可用（30名有三种生物制剂使用经验，14名未指明使用哪种生物制剂）。大多数无生物制剂使用经验的患者（68.8%）和总体有生物制剂使用经验的患者（69.4%）表示他们非常可能选择每12周一次的最低给药频率选项（表1）。相比之下，分别只有较少的无生物制剂使用经验的患者（9.1%和16.7%）和有生物制剂使用经验的患者（22.5%和25.3%）表示他们非常可能选择1周和2周的给药间隔选项。在按特定生物制剂使用经验分组的每个队列中，在无乌司奴单抗使用经验的患者中，最常选择的选项是1 - 2周。在有任何乌司奴单抗使用经验的患者中，无论其其他生物制剂使用经验如何，最常选择的选项是每2 - 3个月。
无生物制剂使用经验的患者以及有任何乌司奴单抗使用经验的患者更倾向于最低给药频率间隔。给药间隔可能会影响银屑病生物治疗的共同决策过程。
《药物皮肤病学杂志》。2017年；16(3):220 - 226。
